SEC Form 4 · accession 0000939767-17-000042
EXELIXIS, INC. · EXEL
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Stelios Papadopoulos
Director
Period of report
Mar 20, 2017
Accepted (ET)
Mar 21, 2017 · 7:28 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000939767
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Mar 20, 2017 | M | 10,000 | $10.53 | A | 1,238,471 | D | |
| Common StockF1 | Mar 20, 2017 | S | 10,000 | $21.66 | D | 1,228,471 | D | |
| Common StockF2 | holding | — | — | — | 10,000 | I | By Trust |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Option (right to buy)F3 | $10.53 | Mar 20, 2017 | M | 10,000 | D | May 2, 2007 | May 1, 2017 | Common Stock | 10,000 | 0 | D |
Explanation of responses
- F1Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $21.66 to $21.68. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 1 to this Form 4.
- F2Shares are held by Fondation Sante, of which the Reporting Person is co-trustee.
- F3The option, representing the right to purchase a total of 10,000 shares of Exelixis, Inc. common stock, became fully exercisable on May 2, 2007.